Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 30 mg - capsule, enteric - excipient ingredients: purified talc; macrogol 6000; hyprolose; titanium dioxide; polysorbate 80; methacrylic acid copolymer; sucrose; maize starch; magnesium carbonate hydrate; colloidal anhydrous silica; brilliant blue fcf; purified water; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adults . 1. healing and long-term management of reflux oesophagitis. . 2. healing and long-term management for patients with duodenal ulcer. . 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. . 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). . 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric patients 1 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . 2. healing of erosive oesophagitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lansoprazole, quantity: 15 mg - capsule, enteric - excipient ingredients: hyprolose; polysorbate 80; magnesium carbonate hydrate; sucrose; colloidal anhydrous silica; purified talc; maize starch; macrogol 6000; titanium dioxide; methacrylic acid copolymer; purified water; sorbitan monolaurate; allura red ac; gelatin; sodium lauryl sulfate; fast green fcf; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adults . 1. healing and long-term management of reflux oesophagitis. . 2. healing and long-term management for patients with duodenal ulcer. . 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. . 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). . 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric patients 1 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . 2. healing of erosive oesophagitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 16.7 mg (equivalent: sunitinib, qty 12.5 mg) - capsule - excipient ingredients: sodium hydroxide; propylene glycol; shellac; sodium lauryl sulfate; iron oxide red; mannitol; magnesium stearate; titanium dioxide; povidone; gelatin; croscarmellose sodium - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isotretinoin, quantity: 20 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - isotretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: soya oil; yellow beeswax; hydrogenated soya oil; partially hydrogenated soya oil; gelatin; glycerol; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; brilliant blue fcf; ethanol; purified water; shellac; strong ammonia solution - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; croscarmellose sodium; pregelatinised maize starch; povidone; titanium dioxide; indigo carmine; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - alcept 250 is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. alcept 250 is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: pregelatinised maize starch; povidone; croscarmellose sodium; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmacor mycophenolate 250 is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. pharmacor mycophenolate 250 is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

arthropharm pty ltd - pentosan polysulfate sodium, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin; sodium lauryl sulfate; silicon dioxide - indications as at 5 august 2021: elmiron is indicated for the treatment of interstitial cystitis. relief of symptoms in patients with interstitial cystitis may not be experienced until 6 to 8 weeks of therapy with elmiron. continuing long-term therapy is necessary for persistent relief of symptoms. relief of symptoms may not occur in all patients, and relapse is likely to occur gradually if treatment is discontinued, even after long periods of therapy.